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Introduction 
Obesity is recognized as a world-wide public health problem that has approached 
epidemic proportions in the United States. Obesity increases the risk of developing insulin 
resistance, diabetes, cardiovascular disease, stroke, lung disease, and cancer. The exact cause for 
increased morbidity resulting from obesity is unclear. Recent evidence has revealed that obesity 
is associated with a state of low-grade systemic inflammation that further promotes the risk of 
developing cardiovascular and pulmonary diseases, such as atherosclerosis and asthma [1-3]. In 
obese subjects, adipose tissue secretes specific adipokines leading to infiltration by macrophages 
that further promote the production of inflammatory mediators in concert with adipocytes [4].  
The amount of visceral adipose tissue in obese subjects directly correlates with elevated 
circulating cytokine levels including interleukin (IL-6), tumor necrosis factor-α (TNF-α), and C-
reactive protein (CRP) [5, 6]. Leptin, an adipokine exclusively manufactured by adipocytes, was 
first identified as a satiety factor that induces appetite suppression [7].  Most recently, leptin has 
been identified as a pro-inflammatory adipokine whose up-regulation in the setting of obesity 
leads to the development of a chronic inflammatory state that contributes to inflammatory-
mediated chronic disease [8].  
Consequent to abnormal metabolism, micronutrient deficiencies are common in obese 
individuals across all age groups [9]. In particular, obese subjects have an increased incidence of 
developing zinc deficiency [10-13]. Interestingly, weight loss has been shown to significantly 
increase circulating zinc levels while decreasing the extent of obese-driven morbidity [14]. With 
regard to obesity-derived inflammation, obese subjects that have lower dietary zinc intake 
exhibit more systemic inflammation in parallel with altered lipid profiles when compared to 
similar subjects with normal zinc intake [15]. Further, in a recent randomized, placebo-
controlled, cross-over study conducted in 60 obese children, zinc supplementation significantly 
attenuated plasma levels of glucose and insulin [16].  
Zinc deficiency perturbs innate immune function and enhances inflammation. Among 
children less than 5 years old, zinc deficiency is one of the leading causes of newly acquired 
respiratory and gastrointestinal infections [17]. Our group was the first to report that zinc 
deficiency causes increased systemic inflammation and mortality in response to serious infection 
[18]. Specifically, we have identified that zinc deficiency results in over-activation of the NF-κB 
pathway, a central signal transduction pathway that is responsible for immune activation and 
inflammation. Further, we have shown that zinc supplementation restores normal pathway 
function [19]. Based on the above observations, we postulate that obesity combined with zinc 
deficiency will further promote the development of a chronic, low-grade systemic inflammatory 
state. To counterbalance this pathogenic cycle we predict that zinc supplementation will benefit 
the host by suppressing inflammation.  
The purpose of this study was to determine whether zinc deficiency contributes to 
increased inflammation in the setting of obesity. Since inflammation is a key driver of obesity 
related diseases and zinc modulates inflammation, a lack of zinc may contribute to increased 
inflammation and susceptibility to related diseases. Diet induced models of obesity and zinc 
deficiency were used to examine differences in inflammation and zinc metabolism between zinc 
normal and deficient obese mice.  
  
Methods 
Animal Model of Obesity and Zinc Deficiency 
Four-week old male C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine) were randomly 
assigned to receive either a 60% high fat diet (HFD) (70 parts per million (ppm) Zn; TD.10873; 
Harlan Tekland) or normal matched control diet (ND) (50 ppm Zn; TD. 85420; Harlan Tekland 
with zinc content adjusted to account for a lower caloric density. Body weights were recorded 
every week, and within six weeks mice fed the HFD experienced, on average, a 29% weight gain 
with altered glucose metabolism, thereby establishing a valid model of obesity. After six weeks, 
half of the animals from each group were randomly placed on a zinc deficient diet (Zn-), either 
60% high fat (1 ppm Zn; TD.10872; Harlan Tekland) or normal (1 ppm Zn; TD.85419; Harlan 
Tekland), respective to the original diet, for an additional three weeks. A zinc-free environment 
was carefully maintained during the course of the entire study using deionized water in zinc-free 
containers and stainless steel cages. As previously reported, zinc deficient diets consistently 
result in a ~2.5 fold decrease in plasma zinc levels [19]. Animal studies were conducted in 
accordance with prior approval by The Ohio State University Institutional Animal Care and Use 
Committee. 
Magnetic Resonance Imaging 
Adipose tissue was analyzed by in vivo Magnetic Resonance Imaging (MRI) using a 1.5 T 
Siemens scanner. Kidneys were used as anatomical landmarks and were depicted using a coronal 
gradient echo, T1-weighted localizing sequence (TR/TE 800/1.00). Thirty, axial slices spanning 
the iliac bifurcation to the superior pole of the topmost kidney were obtained using a T1-
weighted gradient echo turbo FLASH protocol (FOV 288/384; TR/TE 230/5.6; NEX=3; BW 
100MHz; time of acquisition ≈ 11 minutes). Adipose tissue area was analyzed using Image J 
software (NIH, Bethesda, Maryland). 
RNA Isolation and Quantitative RT-PCR 
Following the dietary regimen, livers and adipose tissue (inguinal and epididymal) from animals 
were flash frozen for later analysis. Liver RNA was isolated by the TRIzol method (Invitrogen 
Carlsbad, California). Adipose tissue RNA isolation was performed using QIAzol and the 
RNeasy kit (Qiagen, Valencia, California). cDNA synthesis was performed using ThermoScript 
RT-PCR System (Invitrogen). Real-time PCR was performed with the 7900HT Fast Real-Time 
PCR system (Applied Biosystems, Carlsbad, California) using SYBR Green reagents. All 
analyses were normalized against the average cycle threshold number of mouse GAPDH genes. 
The sequences of all the PCR primers are available on request. 
Glucose Tolerance Testing 
Animals were fasted overnight in a clean cage for sixteen hours. Mice were injected with 2 mg 
glucose per gram body weight intraperitoneally. Blood glucose was measured with a Contour 
blood glucose meter (Bayer HealthCare, Mishawaka, Indiana) at 30 minute intervals from 0 to 
120 minutes. Glucose tolerance was evaluated by measuring the area under the curve (AUC) of 
the blood glucose concentration over time.  
Diabetes and Obesity Marker Levels in Plasma 
Multiplex quantification of factors associated with diabetes and obesity was evaluated in mouse 
plasma samples. The concentration of each marker was analyzed using the Bio-Plex Diabetes 
assay that includes ghrelin, resistin, glucagon-like peptide- 1 (GLP-1), glucagon, leptin, 
plasminogen activator inhibitor-1 (PAI-1), gastric inhibitory polypeptide (GIP), and insulin using 
the Bio-Plex 200 Analysis System (Bio-Rad, Hercules, CA). 
Data Analysis 
All data are expressed as mean ± SD. Statistical comparisons among different groups were 
performed using ANOVA. Significance was assumed at a p value of <0.05.  
 
 
 
  
 Results 
Mice maintained on the 60% high fat diet during the course of this study (9 weeks) experienced
on average, a 42% increase in body weight
maintained on the normal diets (Figure 1a).
 
Figure 1. A) High fat intake resulted in an expected increase in total body weight (42 % increase by 9 weeks); 
however, zinc deficiency did not further increase body weight. 
hours following a glucose challenge (2 mg glucose/gram body weight). The area under the curve (AUC) of the 
blood glucose concentrations over time demonstrates an expected decrease in glucose tolerance in mice 
receiving a high fat diet.  Glucose tolerance was not further affected by zinc deficiency as determined by a 
one-way ANOVA with Tukey’s Multiple Comparison Test, # not significantly different. 
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b).  Consistent 
with these observations, qualitative and quantitative MRI analysis of fat tissue showed an 
increase in the total amount of fat in HFD mice, but again there was no difference between 
animals maintained on different zinc intakes (Figure 2b). Measurement of inguinal and 
epididymal fat weight demonstrated that HFD mice had a significant increase in fat content 
compared to ND mice (Figure 2a).  
 
 
 
 
 
 
 
 
Figure 2.  A) Combined epididymal and inguinal fat weights were recorded following nine weeks of high fat 
intake. Animals in the HFD and combined HFD/Zn deficient groups experienced a similar increase in fat 
content as determined by a one-way ANOVA with Tukey’s Multiple Comparison Test, # not significantly 
different. B) Magnetic resonance imaging also showed an increase in fat accumulation in the high fat diet 
groups.  
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Next we determined whether obesity combined with zinc deficiency altered the circulating levels 
of factors associated with obesity-driven inflammation.  Out of the eight factors evaluated, only 
serum leptin levels were changed. In particular, mice maintained on the combined HFD zinc 
deficient diet had the most significant increase in circulating leptin levels.  An expected increase 
in mice maintained only on HFDs was also observed (Figure 3).  There were no differences 
between treatment groups in circulating levels of ghrelin, resistin, glucagon-like peptide-1 (GLP-
1), glucagon, plasminogen activator inhibitor-1 (PAI-1), gastric inhibitory polypeptide (GIP), 
and insulin.  Serum levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) were 
also analyzed but could not be detected in any of the four treatment groups (data not shown).  
 
Figure 3. Serum leptin levels were evaluated at the end of the dietary regimens (Bio-Plex® Pro Diabetes 
Assay).  Circulating leptin levels were elevated in obese animals and further significantly increased in mice 
that were also subject to a zinc deficient diet as evaluated by a one-way ANOVA with Tukey’s Multiple 
Comparison Test, * p<0.05.  Other markers evaluated (but not shown) were unaffected including ghrelin, 
resistin, GLP-1, glucagon, GIP, insulin, and PAI-1.  
 
* 
Knowing that maintaining mice on a zinc restricted diet lowers plasma zinc levels on average 
2.5-fold, we wanted to determine whether changes in zinc metabolism occurred.  To do this we 
measured mRNA levels of Zip14, a zinc transporter, and metallothionein, an intracellular zinc 
binding protein, in liver tissue. We observed a consistent but insignificant decrease in Zip14 
levels in both of the Zn- diet groups. Metallothionein-1 (MT-1) mRNA levels were significantly 
lower in HFD/Zn- liver tissue when compared to HFD liver tissue (Figure 4). Using the same 
assay, we next analyzed RNA extracted from adipose tissue to determine whether mRNA levels 
unique to genes expressed by macrophages were present within this tissue. Analysis of the 
macrophage markers MAC-1, CD68, and ADAM8 in adipose tissue revealed a significant 
increase, suggestive of an increased presence of macrophages, in the HFD/Zn- mice when 
compared to the HFD mice (Figure 5).  
 
 
 
 
 
 
 
Figure 4. Intracellular zinc metabolism is regulated by zinc transporters and metallothionein.  As an 
exploratory component to our study we evaluated the mRNA expression profile of two of these factors within 
liver tissue following different dietary exposures.  RNA levels were quantitatively measured using real-time 
A B * 
PCR. A) Zinc deficiency resulted in decreased metallothionein-1 (MT-1) RNA levels in the livers of the high 
fat diet groups as evaluated by a one-way ANOVA with Tukey’s Multiple Comparison Test, * p<0.05. B) Zinc 
deficiency also resulted in decreased expression of Zip14, a zinc transporter, in liver tissue, but did not reach 
statistical significance. These findings suggest that zinc metabolism may be significantly altered by zinc 
deficiency in the setting of obesity.  The consequences of which remain to be determined. 
 
 
 
 
 
 
 
 
 
       
Figure 5. RNA levels in adipose tissue were 
quantified  using real-time PCR. A-C) CD68, 
ADAM8, and MAC-1 expression was increased in 
HFD/Zn- diet mice when compared to mice 
subject only to a HFD as evaluated by a one-way 
ANOVA with Tukey’s Multiple Comparison Test, 
*p<0.05. These findings are consistent with 
increased inflammation and macrophage 
infiltration, previously identified to be a hallmark 
of obesity-driven systemic inflammation. 
Discussion 
In our investigation, differences between treatment groups and particularly, obese, zinc 
deficient mice were primarily observed at the molecular level. Interestingly, changes in body 
weight, adipose tissue mass, and glucose tolerance in obese mice were not significantly affected 
by zinc deficiency. We predict that this may be in part due to the relatively short dietary regimen 
that clearly did produce obese mice, but may not have been sufficient time to induce a chronic, 
systemic inflammatory state. In future studies, we will consider implementing a longer duration 
of the combined high fat and zinc restricted diet to induce more obesity and inflammation. This 
would be relevant in the context of human disease since obesity and the development of a 
chronic inflammatory state typically take years to manifest.  
Most striking, differences in serum leptin levels were observed within nine weeks of high 
fat intake which was further significantly increased in obese mice in just three weeks of zinc 
deficient intake. Leptin is a regulator of metabolism and inflammation and its production is 
restricted to adipocytes. Specifically, leptin production is induced by cytokines including TNFα, 
IL-1, and IL-6 [20]. Leptin also plays a role in promoting an inflammatory response by inducing 
the production of cytokines in peripheral blood mononuclear cells and macrophages and by 
enhancing macrophage accumulation within adipose tissue, a hallmark of obesity-mediated 
systemic inflammation, by increasing the release of monocyte chemotactic protein-1 (MCP-1) 
[20]. We observed that zinc deficiency led to an increase in serum levels of leptin in obese mice, 
so we speculate that zinc may play a role in directly controlling leptin production, or, in support 
of our hypothesis, zinc deficiency itself may increase inflammation in adipose tissue that in turn 
stimulates leptin production. Further studies will be required to answer these important 
questions.  
Based upon on our preliminary studies which were restricted to mRNA analysis of liver 
tissue, we contend that zinc metabolism is altered in zinc deficient, obese mice. The decrease 
observed in Zip14 levels suggests that less zinc is taken into the cells, which is also consistent 
with the observation that zinc deficiency caused lower MT-1 levels in the liver. Clearly, more 
extensive analysis will need to be conducted so that we can better understand whether changes in 
zinc metabolism directly or indirectly affect development of an inflammatory state in the setting 
of obesity.  
A hallmark characteristic during the development of chronic systemic inflammation in 
obesity is the accumulation of macrophages in adipose tissue. Consistent with this characteristic, 
obese, zinc deficient animals had an increase in RNA levels of macrophage-specific markers that 
were significantly higher than all other treatment groups, including HFD mice. This suggests that 
although zinc deficient, obese mice did not accumulate more adipose tissue and did not have 
elevated levels of cytokines when compared to obese, zinc sufficient mice, their adipose tissue 
had a higher level of inflammation. We believe this suggests that zinc deficiency within only 
three weeks resulted in an increase in inflammation within adipose tissue.  Given more time, we 
predict that changes in adipose function may lead to increased systemic inflammation. Consistent 
with our findings, obese individuals with the same body mass index exhibit an increase in the 
number of macrophages in adipose tissue which is associated with a higher risk of cardiovascular 
disease [21]. Taken together, these findings indicate that the quality, and not just the quantity, of 
adipose tissue is an important factor in the risk for obesity-related disease.  
We predict that zinc deficiency can contribute to the morbidity observed within the obese 
population in that a lack of zinc has the potential to increase inflammation which then may 
increase the risk of developing inflammation-mediated diseases. If correct, zinc supplementation 
has the potential to lower the risk of the progression of obesity to cardiovascular diseases. The 
NF-κB pathway, which has been previously shown by our group to be zinc responsive [19], may 
be involved in the regulation of the innate immune response in obesity; however, further studies 
are required to determine whether this signaling pathway is actually involved. Based on our 
findings, it appears that leptin production in adipose tissue may serve as sensitive biomarker of 
zinc status in obese subjects. Further, this raises many questions regarding whether leptin 
expression is directly regulated by zinc and whether leptin, or other yet to be identified factors, 
induce macrophage recruitment in the setting of combined zinc deficiency and obesity.  Finally, 
if zinc directly regulates the adipose response, then further studies that evaluate zinc metabolism 
within adipose tissue will be required.  
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